Skip to playerSkip to main content
  • 21 hours ago

Category

People
Transcript
00:00Universal Cancer Vaccine shows promise for treating multiple forms enters human testing.
00:06In 2025, with 2,041,910 new cases and 618,120 deaths projected in the U.S.,
00:16scientists test a universal, off-the-shelf mRNA cancer vaccine.
00:20In mouse trials, this mRNA vaccine was able to supercharge the effects of immunotherapy,
00:26strengthening the immune system as if combating a virus.
00:32A shot at a future without cancer, scientists move closer to a universal vaccine that empowers
00:38the immune system to fight tumors like it would a virus. According to the study conducted on mice
00:43by the University of Florida, combining the new vaccine with the typically used immune checkpoint
00:48inhibitors prompted a strong anti-tumor response in their trials. Instead, the new vaccine simply
00:54boosts the immune system. This new vaccine represents a third possibility. And so this
01:00has significant potential to be broadly used across cancer patients, even possibly leading
01:05us to an off-the-shelf cancer vaccine, stated the study's co-author, Dwayne Mitchell.
01:13According to UF Health, this latest breakthrough has built upon previous successful trials by the
01:18same research team led by Sayur. The first human clinical trial for an mRNA vaccine took place in
01:242024, rapidly reprogramming patients' immune systems to fight against glioblastoma. With this new trial,
01:32the researchers set out to create a generalized mRNA vaccine that supercharged immunity rather than
01:38attacking mutated cancer cells. Across mouse models of melanoma, brain, bone, and skin,
01:43mRNA formulations made resistant tumors respond or disappear, and reactivated T cells to attack cancer.
01:53The team is currently aiming to improve its existing formulations and start human clinical trials
01:58as soon as possible. Now, it is up to human trials to verify that the treatment is truly safe and effective.
Be the first to comment
Add your comment

Recommended